Peptides: the next drug modality stack

Peptides: the next drug modality stack

A new drug modality is emerging — AI is accelerating design, GLP-1 proves demand, and manufacturing is becoming the bottleneck.

Demand & applications

8 companies

Metabolic & obesity (GLP-1 proven)

6 companies

Kailera Therapeutics

Metsera

Viking Therapeutics

Structure Therapeutics

Zealand Pharma

MBX Biosciences

Anchors

2 companies

Novo Nordisk

Eli Lilly

Core innovation

19 companies

AI-driven design & discovery

5 companies

Generate Biomedicines

Absci

Peptilogics

Pepticom

Nuritas

Therapeutics platforms

5 companies

Bicycle Therapeutics

PepGen

PeptiMimesis

PeptiDream

Amolyt Pharma

Delivery & oral bioavailability

5 companies

Rani Therapeutics

Enteris BioPharma

Oramed

Vivtex

Biograil

Discovery, screening & tools

4 companies

Orbit Discovery

Aralez Bio

Pepscan

Unnatural Products

Infrastructure & manufacturing

5 companies

Scale-up (the bottleneck)

5 companies

Bachem

PolyPeptide Group

CordenPharma

AmbioPharm

WuXi AppTec